Literature DB >> 17653654

High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH.

Masato Yoneda1, Hironori Mawatari, Koji Fujita, Hiroshi Iida, Kyoko Yonemitsu, Shingo Kato, Hirokazu Takahashi, Hiroyuki Kirikoshi, Masahiko Inamori, Yuichi Nozaki, Yasunobu Abe, Kensuke Kubota, Satoru Saito, Tomoyuki Iwasaki, Yasuo Terauchi, Shinji Togo, Shiro Maeyama, Atsushi Nakajima.   

Abstract

BACKGROUND: The changes in nonalcoholic fatty liver disease (NAFLD) range over a wide spectrum, extending from steatosis to steatohepatitis (NASH). However, it has remained difficult to differentiate between NASH and nonprogressive NAFLD by clinical examination. We investigated the interrelationships between serum high-sensitivity C-reactive protein (hs-CRP) and the pathogenesis and progression of NASH.
METHODS: Hs-CRP was measured in 100 patients with histologically verified NAFLD (29 with steatosis and 71 with NASH), and a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis was performed to measure the intrahepatic mRNA expressions of CRP and interleukin (IL)-6.
RESULTS: The results of a multiple regression analysis revealed that in comparison with cases of steatosis, hs-CRP was significantly elevated (P = 0.0048) in cases of NASH. Furthermore, among patients with NASH, hs-CRP was significantly elevated in those with advanced fibrosis compared with that in those with mild fibrosis (P = 0.0384), even after adjustment for age, sex, presence of diabetes, body mass index, visceral fat area, subcutaneous fat area, homeostasis model assessment for insulin resistance, high-density lipoprotein cholesterol, triglyceride, and low-density lipoprotein cholesterol. The results of the RT-PCR analysis showed that intrahepatic mRNA expression of CRP, but not IL-6, was increased in patients with NASH compared with those with steatosis (P = 0.0228).
CONCLUSIONS: This is the first report to demonstrate consistent and profound elevation of hs-CRP in cases of NASH compared with in cases of simple nonprogressive steatosis. Our results suggest that hs-CRP may be a clinical feature that not only distinguishes NASH from simple nonprogressive steatosis but also indicates the severity of hepatic fibrosis in cases of NASH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17653654     DOI: 10.1007/s00535-007-2060-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  45 in total

1.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

2.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.

Authors:  W Koenig; M Sund; M Fröhlich; H G Fischer; H Löwel; A Döring; W L Hutchinson; M B Pepys
Journal:  Circulation       Date:  1999-01-19       Impact factor: 29.690

3.  Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults.

Authors:  Seung H Park; Woo K Jeon; Sang H Kim; Hong J Kim; Dong I Park; Yong K Cho; In K Sung; Chong I Sohn; Dong K Keum; Byung I Kim
Journal:  J Gastroenterol Hepatol       Date:  2006-01       Impact factor: 4.029

4.  Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.

Authors:  John Willy Haukeland; Jan Kristian Damås; Zbigniew Konopski; Else Marit Løberg; Terese Haaland; Ingeborg Goverud; Peter A Torjesen; Kåre Birkeland; Kristian Bjøro; Pål Aukrust
Journal:  J Hepatol       Date:  2006-03-20       Impact factor: 25.083

5.  Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.

Authors:  Jason M Hui; James G Kench; Shivakumar Chitturi; Archana Sud; Geoffrey C Farrell; Karen Byth; Pauline Hall; Mahbub Khan; Jacob George
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

6.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

7.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

Review 8.  Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?

Authors:  Geoffrey C Farrell
Journal:  J Gastroenterol Hepatol       Date:  2003-02       Impact factor: 4.029

9.  Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men.

Authors:  Seung Ha Park; Byung Ik Kim; Jung Won Yun; Jeong Wook Kim; Dong Il Park; Yong Kyun Cho; In Kyung Sung; Chang Young Park; Chong Il Sohn; Woo Kyu Jeon; Hyang Kim; Eun Jung Rhee; Won Young Lee; Sun Woo Kim
Journal:  J Gastroenterol Hepatol       Date:  2004-06       Impact factor: 4.029

10.  The natural history of nonalcoholic fatty liver: a follow-up study.

Authors:  M R Teli; O F James; A D Burt; M K Bennett; C P Day
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

View more
  88 in total

1.  Pro- and anti-inflammatory cytokines in steatosis and steatohepatitis.

Authors:  Fabiola Rabelo; Claudia P M S Oliveira; Joel Faintuch; Daniel F C Mazo; Vicencia M R Lima; Jose Tadeu Stefano; Hermes V Barbeiro; Francisco G Soriano; Venancio A Ferreira Alves; Flair J Carrilho
Journal:  Obes Surg       Date:  2010-07       Impact factor: 4.129

2.  Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Christine Carter-Kent; Michael Elias; Ariel E Feldstein
Journal:  Clin Lipidol       Date:  2011-06-01

3.  Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis.

Authors:  Giovanni Targher; Lorenzo Bertolini; Stefano Rodella; Giuseppe Lippi; Giacomo Zoppini; Michel Chonchol
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-19       Impact factor: 8.237

Review 4.  Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.

Authors:  Enzo Bonora; Giovanni Targher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-08       Impact factor: 46.802

Review 5.  Dairy Foods and Dairy Fats: New Perspectives on Pathways Implicated in Cardiometabolic Health.

Authors:  Kristin M Hirahatake; Richard S Bruno; Bradley W Bolling; Christopher Blesso; Lacy M Alexander; Sean H Adams
Journal:  Adv Nutr       Date:  2020-03-01       Impact factor: 8.701

6.  High-sensitivity C-reactive protein and metabolic syndrome (insulin resistance syndrome), including nonalcoholic steatohepatitis.

Authors:  Eiji Oda; Kenichi Watanabe
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

Review 7.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 8.  Effects of exercise training on chronic inflammation in obesity : current evidence and potential mechanisms.

Authors:  Tongjian You; Nicole C Arsenis; Beth L Disanzo; Michael J Lamonte
Journal:  Sports Med       Date:  2013-04       Impact factor: 11.136

9.  The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity.

Authors:  Jun-ichi Takino; Yuka Kobayashi; Masayoshi Takeuchi
Journal:  J Gastroenterol       Date:  2010-01-19       Impact factor: 7.527

10.  Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD.

Authors:  L Maria Belalcazar; George D Papandonatos; Bahar Erar; Inga Peter; Hadeel Alkofide; Ashok Balasubramanyam; Ariel Brautbar; Steven E Kahn; William C Knowler; Christie M Ballantyne; Jeanne M McCaffery; Gordon S Huggins
Journal:  Circ Cardiovasc Genet       Date:  2015-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.